Scientific Reports · 2019 · 27 citations · 29 references
MedicineOncologySurgeryNeuro-oncologySurgical OncologySurvival AnalysisBrain TumorsCancer Survival AnalysisMalignant NeoplasmsPrognostic AssessmentTumor ClassificationCancer Prognostic ModelingDecision Tree ClassificationDecision-tree AnalysisDisease-specific SurvivalPatient-specific Prognosis ModelingPredictionPrognostic Factors AnalysisRegistry-based Survival Statistics
Because the study population with gliosarcoma (GSM) is limited, the understanding of this disease is insufficient. In this study, the authors aimed to determine the clinical characteristics and independent prognostic factors influencing the prognosis of GSM patients and to develop a nomogram to predict the prognosis of GSM patients after craniotomy. A total of 498 patients diagnosed with primary GSM between 2004 and 2015 were extracted from the 18 Registries Research Data of the Surveillance, Epidemiology, and End Results (SEER) database. The median disease-specific survival (DSS) was 12.0 months, and the postoperative 0.5-, 1-, and 3-year DSS rates were 71.4%, 46.4% and 9.8%, respectively. We applied both the Cox proportional hazards model and the decision tree model to determine the prognostic factors of primary GSM. The Cox proportional hazards model demonstrated that age at presentation, tumour size, metastasis state and adjuvant chemotherapy (CT) were independent prognostic factors for DSS. The decision tree model suggested that age <71 years and adjuvant CT were associated with a better prognosis for GSM patients. The nomogram generated via the Cox proportional hazards model was developed by applying the rms package in R version 3.5.0. The C-index of internal validation for DSS prediction was 0.67 (95% confidence interval (CI), 0.63 to 0.70). The calibration curve at one year suggested that there was good consistency between the predicted DSS and the actual DSS probability. This study was the first to develop a disease-specific nomogram for predicting the prognosis of primary GSM patients after craniotomy, which can help clinicians immediately and accurately predict patient prognosis and conduct further treatment.
29
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Robert L. Camp, Marisa Dolled‐Filhart, David L. Rimm · Clinical Cancer Research · 2004 · 3.9K citations
Medicine, Biostatistics, Oncology +17
Evaluating the Yield of Medical Tests
Frank E. Harrell · JAMA · 1982 · 3.4K citations
CGCG clinical practice guidelines for the management of adult diffuse gliomas
Tao Jiang, Ying Mao, Wenbin Ma et al. · Cancer Letters · 2016 · 650 citations · Full text
Medicine, Neurosurgery, Oncology +17
Sarcoma arising in glioblastoma of the brain.
Irwin Feigin, Sidney W. Gross · PubMed · 2003 · 188 citations